title: [Comparison of three HIV antibody confirmatory assay kits in confirming early HIV infection].
abstract: OBJECTIVE
  This study was to compare the performance of three HIV antibody confirmatory assay kits in confirming early HIV infection.
  
  
  METHODS
  Five HIV antibody-positive plasma specimens were ten-fold serially diluted and then detected by ELISA. The above diluted specimens were detected with the following three HIV antibody confirmatory assay kits to analyze their sensitivity, including Wantai-RIBA (Recombinant immunoblot assay, Beijing Wantai Biological Pharmacy, China), MP-WB (HIV Blot 2.2 WB, MP Biomedicals Asia Pacific Pte. Ltd., Singapore) and INNO-LIA (INNO-LIA(TM) HIV I/II Score, Innogenetics N.V., Belgium), respectively. These kits were further used to detect 48 ELISA-reactive specimens from 11 sets of HIV seroconversion specimens (a total of 48 samples) which were previously detected as HIV antibody-positive by ELISA.
  
  
  RESULTS
  When 5 samples were diluted to 100 fold, Wantai-RIBA still can detect them positive. Among the 48 HIV antibody-positive specimens detected with ELISA, the confirmation positive rate for Wantai-RIBA, MP-WB and INNO-LIA were 97.92% (47/48), 81.25% (39/48) and 91.67% (44/48), respectively. There was statistically significant difference between the confirmatory results of Wantai-RIBA and MP-WB (χ(2) = 6.13, P < 0.05), as well as between those of INNO-LIA and MP-WB (χ(2) = 5.48, P < 0.05); however, there was no statistically significant difference between those of Wantai-RIBA and INNO-LIA (χ(2) = 1.33, P > 0.05). For other six HIV seroconversion panels containing indeterminate specimens, the average seroconversion period of time for Wantai-RIBA, MP-WB and INNO-LIA were 0.7, 13.3 and 3.7 days, respectively.
  
  
  CONCLUSIONS
  Compared with MP-WB, Wantai-RIBA and INNO-LIA could reduce the window period to confirm early HIV infection.
authors.affiliation: National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Zeng-qiang
authors.initials: ZQ
authors.lastname: Wang
authors.forename: Gui-yun
authors.initials: GY
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Jiang
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Hua-zhou
authors.initials: HZ
authors.lastname: Jiang
authors.forename: Sheng
authors.initials: S
authors.lastname: Shen
authors.forename: Pin-liang
authors.initials: PL
authors.lastname: Pan
authors.forename: Bo
authors.initials: B
authors.lastname: Liu
authors.forename: Mao-feng
authors.initials: MF
authors.lastname: Qiu
mesh_terms: D042241:Early Diagnosis; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000175:diagnosis*; D006801:Humans; D011933:Reagent Kits, Diagnostic
chemical_list: D015483:HIV Antibodies; D011933:Reagent Kits, Diagnostic